Semaglutide May Boost or Block Chemotherapy Depending on the Drug Pairing
A combined genetic, cellular, and mouse study finds that semaglutide strengthens gemcitabine's antitumor effect by suppressing RRM1 while weakening methotrexate ...
A combined genetic, cellular, and mouse study finds that semaglutide strengthens gemcitabine's antitumor effect by suppressing RRM1 while weakening methotrexate ...
A prospective phase II pilot study from non-endemic Sichuan reports 95.2 percent response rates and 80 percent event-free survival at ...
A retrospective study of 313 patients found that baseline renal impairment doubled the risk of rash during gemcitabine plus nab-paclitaxel ...
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
A systematic review of five real-world studies finds that a biweekly gemcitabine and nab-paclitaxel schedule matches standard survival outcomes in ...
New laboratory research shows progesterone increases vasohibin-2 expression and tubulin detyrosination in progesterone receptor-negative ovarian cancer cells, sharply boosting their ...
A nationwide survey of 120 Chinese physicians reveals that most patients with advanced biliary tract cancer never receive guideline-recommended immunotherapy ...
A prospective Phase II trial in Japan found that biweekly gemcitabine plus nab-paclitaxel produced a 47.1 percent response rate and ...
The phase 1 GlutaPanc trial shows that l-glutamine can be safely combined with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine